Cytek Biosciences Closes Series D Funding with $120M
Cytek Biosciences announced the closing of a $120 million Series D funding round, co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYFE Capital also participating. The investment will be used to expand Cytek’s global infrastructure and maintain growth. RA Capital and Hillhouse Capital have also joined Cytek’s board of directors.
“Cytek is ushering in flow cytometry’s next chapter with its proven, unique combination of innovative technologies,” said Andrew Levin, managing director of RA Capital. “We are excited to join them on their mission to advance cancer and cell biology research.”
LATEST NEWS
- Himax Invests in, Collaborates with Fiber Interconnect Specialist FOCI
Jun 12, 2024
- Sheba Adds Senior Strategic Advisor: People in the News: 6/12/24
Jun 12, 2024
- Photonic Insulator Offers Platform for Study of Light-Matter Interaction
Jun 11, 2024
- Erbium Laser Miniaturized to Chip-Scale
Jun 11, 2024
- Chip-Based 3D Printer for Prototyping on the Go
Jun 10, 2024
- Omega Optical Names CEO
Jun 10, 2024
- Quantinuum Launches 56-Qubit Quantum Computer: Week in Brief: 6/7/2024
Jun 7, 2024
- Atom Computing Lands Investment, Expands Overseas
Jun 7, 2024